Table 1.
Various fractionation schedules, number of applications, biological equivalent doses, and specific pros and cons remarks for each published
| Schedule | No. of applications | EQD2 doses for tumor in Gy (α/β-10) for BT | Remarks | Reference |
|---|---|---|---|---|
| 5-6 Gy × 5-6 fractions | 5-6 | 37.5-40 | Increased risk of exposure due to large number of applications | [20] |
| 7 Gy × 4 fractions | 2 | 39.7 | Limited applications, without compromising the number of fractions | [16] |
| 8 Gy × 3 fractions | 3 | 36 | Overall treatment time may be prolonged if not interdigitated with EBRT | [22] |
| 9 Gy × 2 fractions | 2 | 28.5 | Compromised local control, especially for large volume residual | [20,21] |
| 9 Gy (on day 1) followed by 7 Gy × 2 fractions (on day 2, delivered at least 6 hours apart) | 1 | 34.1 | Risk of exposure reduced, logistic advantage; early outcomes encouraging Long-term outcomes awaited |
Unpublished (CTRI/2017/ 03/008172, SIMBRACE study, Tata Memorial Hospital, Mumbai) |